Zhiting Tang
@ZhitingT
Followers
34
Following
98
Media
3
Statuses
48
hematology oncology fellow @ University of Missouri. Lung cancer & precision oncology
Joined June 2024
RT @dr_yakupergun: Oxaliplatin in Stage II–III CRC: Age Matters. 🔹 Stage III, ≤70 yrs → OS benefit .🔹 Stage III, >70 yrs → No OS gain.🔹 Sta….
0
86
0
RT @MariaGemelli89: 📢 Now Online! . Happy to share our latest meta-analysis on the role of ICIs in PD-L1 negative NSCLC. Grateful to all t….
0
6
0
RT @dr_yakupergun: The next generation of immunotherapies for lung cancers. Although there are many drugs currently in development, my curr….
0
38
0
RT @EricTopol: Cancer vaccines will be a big part of the future of immunotherapy. A new, super review @TheLancet .h….
0
467
0
RT @PatelOncology: Great (free) article in @ASCO Educational Book on innovations and best practices for AI use in oncology and clinical tri….
0
32
0
RT @BalazsHalmosMD: Do we have any MRD (minimal residual doubt) that MRD assays will make a major impact in risk stratification in periop/p….
0
3
0
RT @CharlesJiangMD: Another way to frame the question: If a pharmaceutical company could sell exercise as a drug—given its well-established….
0
2
0
RT @oncology_bg: The most practice changing trial from #ASCO25 is now live on @NEJM .If this was a drug, this would be approved today. Glob….
0
304
0
Thanks for sharing!.
#lcsm / #pathtwitter friends.In the work-up of mediastinal masses - if you are smart, you do not forget about SMARCA4. See below case-based overview of:.☑️differential dx guide.☑️path/molecular work up of novel entities.☑️biology/emerging treatment approaches . Reading this
0
0
0
Interesting read!.
“Skimming the median” – when winning arm hovers over median OS for long period, comparing median OS b/w groups results in exaggerated perceived benefit. ESOPEC given as ex, & I agree. FLOT outperformed CROSS, but stating FLOT extends OS by 29 mo is misleading. Great viewpoint!
0
0
0
RT @CharlesJiangMD: Heading to #ASCO25 for the first time as a trainee? It can be overwhelming but also incredibly rewarding! Here’s some h….
0
14
0
RT @SuyogCancer: Genetic blood test for cancer screening of healthy individual With no family history of cancer is how precision Oncology….
0
5
0
RT @IMG_Oncologists: 🚨Save the date🚨.@ASCO #IMG Community of Practice Meeting at #ASCO25.⏰May 30st, 4-6 PM CST.📌Room S103, McCormick Place….
0
41
0
RT @JoeChangMD: Re-irradiation is common but challenging in lung cancer. ARS just published: American Radium Society™ Appropriate Use Crit….
0
55
0
RT @SuyogCancer: Top 10 Breast Cancer Trials to Watch at #ASCO25.Save the date ⏰ Big data in HER2+, TNBC & HR+ mBC!.1️⃣ DESTINY-Breast09 –….
0
97
0
RT @BalazsHalmosMD: I heard the nicest line from a colleague a few days ago as to how to introduce a regimen with many adverse events to pr….
0
2
0